ArticlePloS one2017
Boosting efferocytosis in alveolar space using BCG vaccine to protect host against influenza pneumonia.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 69 citations in OpenAlex.
- Integrative profiling of transcriptome and H3K27ac modification reveals changes associated with BCG-induced trained immunity in bovine immune cells.Scientific reports · 2026Article
- Evaluation of trained immunity as a potential strategy for a universal Streptococcus suis vaccine using immunogenic proteins in a murine model.BMC veterinary research · 2026Article
- Unleashing the power of the BCG vaccine in modulating viral immunity through heterologous protection: A scoping review.Human vaccines & immunotherapeutics · 2025Article
- Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity.Cancer cell · 2025Article
- BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs.JCI insight · 2025Article
- Infection-induced trained immunity: a twist in paradigm of innate host defense and generation of immunological memory.Infection and immunity · 2025Review
- Alveolar Macrophages in Viral Respiratory Infections: Sentinels and Saboteurs of Lung Defense.International journal of molecular sciences · 2025Review
- The impact of mycobacteria-induced trained immunity on SARS-CoV-2 vaccine responses.Frontiers in immunology · 2025Article
- Multifaceted roles of trained immunity in diverse pathological contexts.BMB reports · 2024Review
- Review
- Interstitial Macrophages Mediate Efferocytosis of Alveolar Epithelium during Influenza Infection.American journal of respiratory cell and molecular biology · 2024Article
- Editorial: Vaccine-induced innate immunity and its role in viral infections.Frontiers in immunology · 2024Article
- Efferocytosis and Respiratory Disease.International journal of molecular sciences · 2023Review
- A "trained immunity" inducer-adjuvanted nanovaccine reverses the growth of established tumors in mice.Journal of nanobiotechnology · 2023Article
- Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19.Frontiers in immunology · 2023Review
- Prophylactic and therapeutic insights into trained immunity: A renewed concept of innate immune memory.Human vaccines & immunotherapeutics · 2022Review
- Vaccination Strategies in a Potential Use of the Vaccine against Bovine Tuberculosis in Infected Herds.Animals : an open access journal from MDPI · 2022Review
- Review
- BCG Vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents.International immunopharmacology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efferocytosis by alveolar phagocytes (APs) is pivotal in maintenance of lung homeostasis. Increased efferocytosis by APs results in protection against lethal acute lung injury due to pulmonary infections whereas defective efferocytosis by APs results in chronic lung inflammation. In this report, we show that pulmonary delivery of Bacillus Calmette-Guerin (BCG) significantly enhances efferocytosis by APs. Increased efferocytosis by APs maintains lung homeostasis and protects mice against lethal influenza pneumonia. Intranasally treated wild type C57Bl/6 (WT) mice with BCG showed significant increase in APs efferocytosis in vivo compared to their PBS-treated counterparts. All BCG-treated WT mice survived lethal influenza A virus (IAV) infection whereas all PBS-treated mice succumbed. BCG-induced resistance was abrogated by depleting AP prior to IAV infection. BCG treatment increased uptake, and digestion/removal of apoptotic cells by APs. BCG significantly increased the expression of TIM4 on APs and increased expression of Rab5 and Rab7. We demonstrated that increased efferocytosis by APs through pulmonary delivery of BCG initiated rapid clearance of apoptotic cells from the alveolar space, maintained lung homeostasis, reduced inflammation and protected host against lethal IAV pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.